Clinical Trials & Studies

Referring Physicians – the following is technical details for your information and in the event you have patients you feel might be appropriate to refer. Please contact the person listed for the specific trial or study, or the lead investigator.

Geographic Atrophy in Dry AMD

Andre Witkin, MD

Title: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration

Brief Summary
To assess the safety and effectiveness of the investigational drug ORACEA®, to determine if it can slow the progression of geographic atrophy in your study eye in participants who have geographic atrophy secondary to non-exudative age-related macular degeneration (dry AMD). 

Inclusion Criteria

  • Participants aged 50-85 years
  • Clinical diagnosis of geographic atrophy secondary to non-exudative age-related macular degeneration in at least one eye as confirmed color fundus photography.

Study Requirements
8 study visits over a 31-month period with additional testing
Age Range

55-85

Gender
Both

Payment
None

Contact: Carly Satsuma, 617-636-5489

Age-Related Macular Degeneration (AMD) and Other Macular Disorders

Etiologic Studies of Age Related Macular Degeneration

Principal Investigator: Johanna M. Seddon, MD., ScM

Definition: AMD is a retinal degenerative disease that causes a progressive loss of central vision. AMD is the most common cause of vision loss in individuals age 60 years and older. Juvenile onset forms of macular degeneration, like Stargardt and Best disease, also can cause severe loss of vision.

Target Population: Individuals with macular degeneration (wet or dry) and spouses, siblings and adult children (with or without AMD), including age-related and juvenile onset forms of macular degeneration.

Duration: On-going since 1989.

Purpose: The purpose of this research study is to determine the causes of macular degeneration so we can prevent it and find better treatments. We will continue to identify genes and environmental determinants of macular degeneration. Eligible study participants will have an eye exam and blood draw. Participants will also complete questionnaires on diet and risk factors.

Click Here for full details

YOU DO NOT NEED TO LIVE IN THE BOSTON AREA TO PARTICIPATE.

Contact: Project Manager, Ophthalmic Epidemiology and Genetics Service
New England Eye Center
Tufts Medical Center
800 Washington Street #450
Boston, MA 02111
617-636-9000 or toll free: 800-219-9157

Pediatric Amblyopia

Primary Investigator: Vicki Chen, MD

Title: Novel Video Based Therapy for Children with Amblyopia

Inclusion Criteria
Group #1: Age 4-10 years, untreated or minimally treated amblyopia with possible need for patching/atropine, BCVA in amblyopic eye 20/30 to 20/80, 20/30 or better in fellow eye, no previous intraocular or refractive surgery, no coexisting ocular, neurological or systemic disease that could impact visual acuity assessment Group #2: Age 4-15 years, amblyopia, one or more other eye conditions with amblyopic component, BCVA in amblyopic eye 20/30 to 20/80, 20/30 or better in fellow eye

Risk: Minimal, including possible temporary headaches, double vision, eye strain timeframe

Benefit: Alternative treatment to patching/atropine, potential improvement in vision Study Length and Visits: 16 weeks, 4 visits (5 visits including enrollment visit)

Payment: None

Contact: Principal Investigator Dr. Vicki Chen, Co-Investigators Dr. Catherine Choi, Dr. Nicole Quinn, Dr. Mitchell Strominger, Dr. Sylvia Yoo, or Shelley Klein: 617-636-6769

Contact Lens Discomfort & Neuropathic Corneal Pain

Primary Investigator: Pedram Hamrah, MD

Title: Assessment of Cellular and Soluble Mediators in Contact Lens Discomfort and Neuropathic Corneal Pain

Sponsor: CooperVision

Brief Summary

Inclusion Criteria

  • Group I (symptomatic CL wearers): over the age of 18, willing and able to commit and consent to IVCM and tear collection, have had daily contact lens wear experience, report a comfortable wearing time (CWT) <8 hours, noticeable reduction in comfort over the course of the day and a score of ≥14 by CLDEQ-8
  • Group II (Asymptomatic CL wearers): over the age of 18, willing and able to commit and consent to IVCM and tear collection and have had daily contact lens wear experience, report a CWT > 10 hours, minimal reduction in comfort over the course of the day (i.e. lens wearing time less CWT < 1hr) and a score of <14 by CLDEQ-8
  • Group III (Intolerant CL wearers): over the age of 18, willing and able to commit and consent to IVCM and tear collection, and have stopped CLW due to discomfort symptoms arising in the first 6 hours of lens wear.
  • Group IV (Neuropathic corneal pain patients): over the age of 18, willing and able to commit and consent to IVCM and tear collection and have neuropathic corneal pain as diagnosed clinically and by IVCM.
  • Group V (Normal subjects): over the age of 18, willing and able to commit and consent to IVCM and tear collection.

Study Length and Visits: 1 to 2 study visits

Age Range: > 18 years old

Payment: $50 for participation

Contact: Mildred Commodore, 617-636-1051 or Carly Satsuma, 617-636-5489

No Dry Eye Disease (DED) – 2 patients needed

Primary Investigator: Pedram Hamrah, MD

Title: Ocular Surface Immune Response in Dry Eye Disease: Analysis of Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation

Sponsor: Allergan

Inclusion Criteria
No eye disease/infection/surgery within the past year, No dry eye symptoms (e.g. itching, burning, light sensitivity), No history of DED or Diabetes, General good health, Does not wear contact lenses or currently use eye medications.

Study Length and Visits: One visit

Age Range: 40+ years

Payment: $50 for participation in study

Contact: Mildred Commodore, 617-636-1051 or Carly Satsuma, 617-636-5489

Dry Eye Disease (DED)

Primary Investigator: Pedram Hamrah, MD

Title: The utility of in vivo confocal microscopy to assess cellular response and efficacy of long-term topical steroid treatment in patients with dry eye disease

Sponsor: GlaxoSmithKline plc

Inclusion Criteria
Symptoms of DED for at least 6 months, 2 or more of the following: Schirmer test <10mm at 5 minutes, TBUT <10 seconds, Corneal fluorescein staining of 4 (NEI grading) in at least one eye, Lissamine green staining of nasal & temporal conjunctiva (NEI grading) in at least one eye, Corneal dendritiform cell count by confocal microscopy of >=75/mm2 

Study Length and Visits: 3 study visits over 6 week period

Age Range: 18-89 years

Payment: $50 per visit

Contact: Mildred Commodore, 617-636-1051 or Carly Satsuma, 617-636-5489

AMD and Macular Dystrophies

Primary Investigator: Johanna Seddon, MD

Title: Genetic and Non-genetic Biomarkers for Macular Degeneration and Macular Dystrophy

Sponsor: NIH

Inclusion Criteria: Dry and Wet AMD, Stargardt, Best, High Myopia, other Macular Dystrophies

Age Range: Any, and normal patients age 65+

Payment: None, but ***Patients do not need to come into Boston to participate***

Contact: Dr. Seddon’s Study Staff: 6-9000

`

Geographic Atrophy in Dry AMD

Primary Investigator: Nadia Waheed, MD

Title: MAIA 2 Microperimetry in Geographic Atrophy

Sponsor: Johnson & Johnson

Inclusion Criteria: Age-related macular degeneration with geographic atrophy, BCVA of 20/80-20/800, refraction of +10.00D to -8.00D, up to 4.00D of astigmatism

Study Length and Visits: 2 visits within 6 months

Age Range: 55-90

Payment: $100 on completion of 2 visits, Transportation up to an additional $60

Contact: Mildred Commodore, 617-636-1051, Carly Satsuma, 617-636-5489

AMD

Primary Investigator: Nadia Waheed, MD

Title: High-Field MRI of Intracranial Vasculature at MGH

Inclusion Criteria: AMD, No contraindications to MRI Scanning (electrical implants, ferromagnetic implants or objects, weight > 350 lbs, women of childbearing age seeking to become pregnant or may be pregnant, pre-existing medical condition likely to develop seizures or claustrophobic reactions, and greater than normal potential for cardiac arrest)

Study Length and Visits: 1 visit

Age Range: 18+ years

Payment: $150, ***Transportation Provided***

Contact: Carly Satsuma, 617-636-5489, Mildred Commodore, 617-636-1051

Open-Angle Glaucoma or Ocular Hypertension

Primary Investigator: Cynthia Mattox, MD

Title: A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty (SLT) in Patients with Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Sponsor: Allergan

Inclusion Criteria: IOP not adequately managed with topical medication for reasons other than medication efficacy, both eyes can be treated with topical prostamide, prostaglandin, or prostaglandin analog eye drops as sole therapy if medication was taken as directed, IOP can be adequately managed with SLT monotherapy, suitable candidate for SLT, diagnosis of OAG or OHT in each eye requiring bilateral IOP-lowering treatment

Study Length and Visits: 22 study visits and 7 phone calls over approximately 14 months

Age Range: ≥ 18 years old

Payment: $100 per visit

Contact: Mildred Commodore, 617-636-1051, Carly Satsuma, 617-636-5489

Ocular Inflammation and Pain Following Cataract Surgery

Primary Investigator: Pedram Hamrah, MD

Title: A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Sponsor: Bausch & Lomb

Inclusion Criteria:  Be a candidate for routine, uncomplicated cataract surgery, have potential postoperative pin-holed Snellen visual acuity (VA) of at least 20/200 in the study eye at visit 1 and at least 20/200 in the fellow eye

Study Length and Visits:  7 study visits over approximately 4 weeks

Age Range: > 18 years old,

Payment: $20 for Day 2 visit, $100 for Day 1, 3, 4, 5, 6, and 7 visits

Contact: Mildred Commodore, 617-636-1051 or Carly Satsuma, 617-636-5489